Clinical trial
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated…
NCT00001337 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001337 |
|---|---|
| Title | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma |
| Official title | Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma, Gray Zone Lymphoma |
| Intervention type | Biological, Diagnostic Test, Drug, Other, Procedure |
| Interventions | Etoposide, Rituximab, Prednisone, Cyclophosphamide, Vincristine, Doxorubicin, MRI, CT, Biopsy, PET scan and 6 more |
| Enrollment | 348 |
| Start date | May 8, 1993 |
| Primary completion | May 24, 2024 |
| Completion | May 24, 2024 |
| First posted | Nov 4, 1999 |
| Last update posted | Jun 22, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: